Kura Oncology
KURA
165 hedge funds and large institutions have $1.72B invested in Kura Oncology in 2024 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 54 increasing their positions, 48 reducing their positions, and 15 closing their positions.
452% more call options, than puts
Call options by funds: $19.8M | Put options by funds: $3.59M
167% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 15
50% more capital invested
Capital invested by funds: $1.15B → $1.72B (+$570M)
18% more funds holding
Funds holding: 140 → 165 (+25)
13% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 48
1.76% less ownership
Funds ownership: 107.83% → 106.06% (-1.8%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$36.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.8M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$19.4M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$16.9M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$50.3M |
| 2 |
Morgan Stanley
New York
|
-$25.4M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$22.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$21.4M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$12.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CIA
176
Cape Investment Advisory
Mcdonough,
Georgia
| – | -$176K | -12,219 | Closed |
|
|
BHCM
177
Brevan Howard Capital Management
St. Helier,
Jersey
| – | -$171K | -11,891 | Closed |
|
|
A
178
AlphaQuest
New York
| – | -$4.93K | -343 | Closed |
|
|
C
179
Covestor
London,
United Kingdom
| – | -$78 | -4 | -40% |
|
180
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$78 | +4 | New |
|
KURA Hedge Fund Activity: Q1 2024 in Review
165 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2024, worth a combined $1.72B — up 50% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new KURA positions and 15 closed out — a net gain of 25 holders — while 54 added to existing stakes and 48 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $36.4M. The largest seller was BVF Inc, cutting an estimated $50.3M.
- 165 institutional investors held Kura Oncology (KURA) as of Q1 2024, up from 140 in Q4 2023.
- Funds reported $1.72B of Kura Oncology stock for Q1 2024, up 50% quarter-over-quarter.
- 40 funds opened new Kura Oncology positions in Q1 2024 and 15 closed out, a net change of +25 holders.
- The largest Kura Oncology buyer in Q1 2024 was Paradigm Biocapital Advisors, an estimated $36.4M added.
- The largest Kura Oncology seller in Q1 2024 was BVF Inc, an estimated $50.3M sold.
Based on aggregated 13F filings for Q1 2024.